Table 3. Genotypic frequencies of CYP2B6*9 (G516T) variant stratified by clinical parameters and lab measurements among B-CLL patients.
| Parameter | GG (n = 41) | GT (n = 39) | TT (n = 20) | p-value | p-value within groups |
|---|---|---|---|---|---|
| Age (years) | 60 (36–77) | 54.5 (45–59) | 52 (42–59) | p < 0.001* | p1 = 0.003* |
| p2 = 0.001* | |||||
| p3 = 0.4 | |||||
| Sex (n%) | p1 = 0.009* | ||||
| Male | 20 (49%) | 30 (77%) | 13 (65%) | p = 0.09 | p2 = 0.2 |
| Female | 21 (51%) | 9 (23%) | 7 (35%) | p3 = 0.32 | |
| CD38 (n%) | |||||
| Negative | 27 (66%) | 28 (72%) | 10 (50%) | p = 0.78 | _______ |
| Positive | 14 (34%) | 11 (28%) | 10 (50%) | ||
| CD49d (n%) | |||||
| Negative | 21 (51%) | 22 (56.5%) | 15 (75%) | p = 0.61 | _______ |
| Positive | 20 (49%) | 17 (43.5%) | 5 (25%) | ||
| Cytogenetics (n%) | |||||
| Normal | 36 (88%) | 19 (51.5%) | 1 (10%) | p < 0.001* | |
| 13q14 del. | 3 (7%) | 10 (23%) | 8 (40%) | p1 = 0.01* | |
| 11q23 del. | 1 (2.5%) | 8 (20.5%) | 9 (45%) | p2 < 0.001* | |
| 17p13 del. | 0 (0%) | 2 (5%) | 2 (20%) | p3 = 0.04* | |
| Trisomy 12 | 1 (2.5%) | 0 (0%) | 0 (0%) | ||
| Binet stage (n%) | |||||
| B | 28 (68%) | 20 (51%) | 11 (55%) | p = 0.81 | _______ |
| C | 13 (32%) | 19 (49%) | 9 (45%) | ||
| Rai stage (n%) | |||||
| ii | 21 (51%) | 16 (41%) | 14 (70%) | ||
| iii | 9 (22%) | 10 (25.5%) | 3 (15%) | p = 1.0 | _______ |
| iv | 11 (27%) | 13 (33.5%) | 3 (15%) | ||
| Lymphocytes (×109/L) | 73 (51–95) | 64.7(43–177.2) | 68.1 (45.5–87.2) | p = 0.96 | _______ |
| β2 microglobulin (mg/L) | 5.5 ± 1.86 | 5.6 ± 1.6 | 4.82 ± 2.1 | p = 1.0 | _______ |
| LDH (U/L) | 290 (188–401) | 288 (180–395) | 281.5 (191–381) | p = 1.0 | _______ |
Note: Chi-square and Kruskal-Wallis tests were used. *: statistically significant (if p < 0.05), p1: comparison of GG vs. GT, p2: comparison of GG vs. TT, p3: comparison of GT vs. TT, LDH: Lactate dehydrogenase.